Santaris Pharma in deal with GlaxoSmithKline to develop RNA-targeted medicines
Santaris Pharma, a Denmark-based clinical-stage biopharma company, has signed an agreement with UK drug giant GlaxoSmithKline (LSE: GSK), whereby, under an option right, GSK gains access to Santaris' Locked Nucleic Acid (LNA) technology to develop RNA-targeted medicines.
Under the terms of the accord, GSK can obtain rights to utilize Santaris’ proprietary Locked Nucleic Acid (LNA) Drug Platform to research, develop and commercialize LNA-medicines targeted against up to three targets. Financial details on the deal were not disclosed.
"We are delighted to do this new deal with GSK," said Henrik Oerum, chief scientific officer and vice president business development of Santaris, adding: "This is the sixth partner deal we have concluded in the past 12 months with pharmaceutical and biotech companies, so it has really been a spectacular year for Santaris Pharma."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze